Catalent, Inc. CTLT | NYSE
Company Overview:
10 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
CTLT Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for CTLT
Based on past 10-year performance, here are CTLT growth metrics:
Share price CAGR of +8.08%
Dividend CAGR of +0%
Using CTLT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| CTLT (DRIP) | CTLT - No DRIP | |
|---|---|---|
| Current Price | $63.48 | $63.48 |
| Start Shares | 157.53 | 157.53 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 157.53 | 157.53 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $127.77 | $63.48 |
| Total Dividends | $0 | $0 |
| Final Value | $20,128 | $10,000 |
NOTE: Above numbers are our estimate based on CTLT's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Catalent, Inc. (CTLT) had its IPO on 2014-07-31, and is trader on NYSE stock exchange.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
CTLT website: https://www.catalent.com
